Promomed Group of Companies has registered a new antitumor drug for the treatment of common cancers

Promomed's oncological portfolio has been replenished with a new drug for the treatment of common forms of colorectal cancer.

Promomed Group of Companies has registered a powerful broad-spectrum antibiotic

Promomed Group of Companies has registered a powerful broad-spectrum antibiotic

The first graduates of the basic department of JSC Biochemist (part of Promomed Group) received diplomas

Promomed Company has registered a new anticancer drug for the treatment of the most common types of cancer

Promomed Group invests in scientific potential of employees

The advantages of the innovative Brainmax® drug from Promomed Group were discussed by the participants of the Neuroforum

Efavirenz is a new drug for the treatment of HIV infection in the Promomed Group's drug portfolio

The corporate wellness program at JSC "Biochemist" of the Promomed group has reduced the morbidity of employees

Promomed's Modelform® is the winner of the Smartpharma® Awards 2022

Sorafenib is a new drug in Promomed Group's cancer portfolio

Promomed Group summed up the results of SPIEF 2022

Promomed Group begins joint work with Skolkovo Foundation

Leading universities of the country will train specialists for Promomed Group of Companies

Promomed Group of Companies at the SPIEF. Day two: "The course for innovation"

Promomed Group of Companies at the SPIEF. Day One: "Drug Safety"

Promomed Group's Biochemist and St. Petersburg State University of Chemistry and Pharmacy signed a memorandum of strategic partnership at the SPIEF

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office